Clearside BioMedical is a late-stage clinical biopharmaceutical company developing drug therapies to treat blinding diseases of the eye. Its product candidates are injected into the suprachoroidal space (SCS) using its proprietary SCS Microinjector.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
